Patents by Inventor Mark Larche

Mark Larche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9850281
    Abstract: Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: December 26, 2017
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Paul Laidler, Pascal Hickey, Mark Larche
  • Patent number: 9744222
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: August 29, 2017
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Paul Laidler, Mark Larche
  • Patent number: 9347937
    Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: May 24, 2016
    Assignee: Circassia Limited
    Inventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
  • Patent number: 9340580
    Abstract: The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerization therapy.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: May 17, 2016
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Mark Larche
  • Patent number: 9168295
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: October 27, 2015
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Mark Larche, Anthony Barrington Kay
  • Publication number: 20150218215
    Abstract: Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.
    Type: Application
    Filed: May 30, 2013
    Publication date: August 6, 2015
    Inventors: Roderick Peter Hafner, Paul Laidler, Pascal Hickey, Mark Larche
  • Patent number: 9017689
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: April 28, 2015
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Paul Laidler, Mark Larche, Christopher Hugh Reginald Stocker
  • Publication number: 20150098969
    Abstract: Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporium genus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a) a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT (Alt28; SEQ ID NO: 101) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b) a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR (Alt34A; SEQ ID NO: 107) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d) a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ (Alt13A; SEQ ID NO: 83) or a T cell epi
    Type: Application
    Filed: May 30, 2013
    Publication date: April 9, 2015
    Inventors: Roderick Peter Hafner, Paul Laidler, Pascal Hickey, Mark Larche
  • Patent number: 8821887
    Abstract: A first or second polypeptide for use in a method of treating or preventing a disorder by tolerization, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class II-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterized by an inappropriate immune response to the protein allergen from which the second polypeptide derives.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: September 2, 2014
    Assignee: Circassia Limited
    Inventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
  • Patent number: 8753644
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: June 17, 2014
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Paul Laidler, Mark Larche, Christopher Hugh Reginald Stocker
  • Patent number: 8652485
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: February 18, 2014
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Paul Laidler, Mark Larche
  • Patent number: 8551492
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: October 8, 2013
    Assignee: Circassia Limited
    Inventors: Roderick Peter Hafner, Mark Larche, Anthony Barrington Kay
  • Publication number: 20130243798
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.
    Type: Application
    Filed: February 15, 2011
    Publication date: September 19, 2013
    Applicant: CIRCASSIA LIMITED
    Inventors: Christopher Hugh Reginald Stocker, Paul Laidler, Mark Larche, Roderick Peter Hafner
  • Patent number: 8491910
    Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: July 23, 2013
    Assignee: Circassia Limited
    Inventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
  • Publication number: 20120148612
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
    Type: Application
    Filed: February 5, 2010
    Publication date: June 14, 2012
    Applicant: CIRCASSIA LIMITED
    Inventors: Roderick Peter Hafner, Paul Laidler, Guy Layton, Christopher Hugh Reginald Stocker, Mark Larche
  • Publication number: 20120108524
    Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.
    Type: Application
    Filed: August 14, 2009
    Publication date: May 3, 2012
    Applicant: CIRCASSIA LIMITED
    Inventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
  • Publication number: 20110206709
    Abstract: A first or second polypeptide for use in a method of treating or preventing a disorder by tolerisation, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class Il-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterised by an inappropriate immune response to the protein allergen from which the second polypeptide derives.
    Type: Application
    Filed: August 14, 2009
    Publication date: August 25, 2011
    Applicant: CIRCASSIA LIMITED
    Inventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
  • Publication number: 20110142867
    Abstract: Methods for desensitising an individual to a selected polypeptide antigen are provided. The methods entail administration of T cell epitope containing peptides from a polypeptide antigen in such a way as to establish a tolergeneic environment, that is, a state of hyporesponsiveness to the peptides. The selected polypeptide antigen is then administered such that the state of hyporesponsiveness and co-administration of the selected antigen are sufficient to desensitise the individual to the polypeptide antigen. Also provided are therapeutic systems useful in the methods of the invention, and the use of polypeptide antigens and peptides in the manufacture of medicaments in the methods of the invention.
    Type: Application
    Filed: August 20, 2010
    Publication date: June 16, 2011
    Inventors: Mark Larche, Philip William Ledger
  • Publication number: 20100298239
    Abstract: The present invention relates to peptides comprising multiple MHC Class II-binding T cell epitopes for tolerisation therapy.
    Type: Application
    Filed: August 15, 2008
    Publication date: November 25, 2010
    Applicant: CIRCASSIA LIMITED
    Inventors: Roderick Peter Hafner, Mark Larche
  • Publication number: 20100260805
    Abstract: The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
    Type: Application
    Filed: August 15, 2008
    Publication date: October 14, 2010
    Applicant: CIRCASSIA LIMITED
    Inventors: Roderick Peter Hafner, Paul Laidler, Mark Larche